The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Feasibility of incorporating molecular profiling into decision-making in HER2-negative G/GEJ cancers
Paolo Manca, MD, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy, comments on the feasibility of incorporating molecular profiling into routine decision-making for maintenance strategies in HER2-negative gastric and gastroesophageal junction (G/GEJ) cancers. Profiling of primary tumors is already established in the United States, making molecular profiling more feasible. In Europe, profiling is not routine, however this may become likely in the future as costs of sequencing technology decrease. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
